Summary

Cell Therapy Market – Scope of Report
TMR’s report on the global cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global cell therapy market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell therapy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cell therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell therapy market.

The report delves into the competitive landscape of the global cell therapy market. Key players operating in the global cell therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell therapy market profiled in this report.

Key Questions Answered in Global cell therapy Market Report
• What is the sales/revenue generated by cell therapy across all regions during the forecast period?
• What are the opportunities in the global cell therapy market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Cell Therapy Market – Research Objectives and Research Approach
The comprehensive report on the global cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell therapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell therapy market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cell Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cell Therapy Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Porter’s Five Forces Analysis
5.2. PEST Analysis
5.3. Key Industry Events - Product Approvals
5.4. Key Industry Events - Partnerships and Collaborations
6. Global Cell Therapy Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2020-2034
6.3.1. T-cell Therapy
6.3.1.1. Chimeric Antigen Receptor (CAR) T-cells
6.3.1.2. T-cell Receptors
6.3.1.3. Tumor-Infiltrating Lymphocytes
6.3.2. Stem Cell Therapy
6.3.3. Natural Killer Cells
6.3.4. Dendritic Cells
6.3.5. Other Cell Therapies
6.4. Market Attractiveness By Type
7. Global Cell Therapy Market Analysis and Forecasts, By Origin
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Origin, 2020-2034
7.3.1. Autologous Therapies
7.3.2. Allogenic Therapies
7.4. Market Attractiveness By Origin
8. Global Cell Therapy Market Analysis and Forecasts, By Therapeutic Area
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Therapeutic Area, 2020-2034
8.3.1. Oncological Disorders
8.3.2. Autoimmune Disorders
8.3.3. Neurological Disorders
8.3.4. Others
8.4. Market Attractiveness By Therapeutic Area
9. Global Cell Therapy Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Cell Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type, 2020-2034
10.2.1. T-cell Therapy
10.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
10.2.1.2. T-cell Receptors
10.2.1.3. Tumor-Infiltrating Lymphocytes
10.2.2. Stem Cell Therapy
10.2.3. Natural Killer Cells
10.2.4. Dendritic Cells
10.2.5. Other Cell Therapies
10.3. Market Value Forecast By Origin, 2020-2034
10.3.1. Autologous Therapies
10.3.2. Allogenic Therapies
10.4. Market Value Forecast By Therapeutic Area, 2020-2034
10.4.1. Oncological Disorders
10.4.2. Autoimmune Disorders
10.4.3. Neurological Disorders
10.4.4. Others
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Origin
10.6.3. By Therapeutic Area
10.6.4. By Country
11. Europe Cell Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2020-2034
11.2.1. T-cell Therapy
11.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
11.2.1.2. T-cell Receptors
11.2.1.3. Tumor-Infiltrating Lymphocytes
11.2.2. Stem Cell Therapy
11.2.3. Natural Killer Cells
11.2.4. Dendritic Cells
11.2.5. Other Cell Therapies
11.3. Market Value Forecast By Origin, 2020-2034
11.3.1. Autologous Therapies
11.3.2. Allogenic Therapies
11.4. Market Value Forecast By Therapeutic Area, 2020-2034
11.4.1. Oncological Disorders
11.4.2. Autoimmune Disorders
11.4.3. Neurological Disorders
11.4.4. Others
11.5. Market Value Forecast By Country/Sub-region, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Origin
11.6.3. By Therapeutic Area
11.6.4. By Country/Sub-region
12. Asia Pacific Cell Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2020-2034
12.2.1. T-cell Therapy
12.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
12.2.1.2. T-cell Receptors
12.2.1.3. Tumor-Infiltrating Lymphocytes
12.2.2. Stem Cell Therapy
12.2.3. Natural Killer Cells
12.2.4. Dendritic Cells
12.2.5. Other Cell Therapies
12.3. Market Value Forecast By Origin, 2020-2034
12.3.1. Autologous Therapies
12.3.2. Allogenic Therapies
12.4. Market Value Forecast By Therapeutic Area, 2020-2034
12.4.1. Oncological Disorders
12.4.2. Autoimmune Disorders
12.4.3. Neurological Disorders
12.4.4. Others
12.5. Market Value Forecast By Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Origin
12.6.3. By Therapeutic Area
12.6.4. By Country/Sub-region
13. Latin America Cell Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2020-2034
13.2.1. T-cell Therapy
13.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
13.2.1.2. T-cell Receptors
13.2.1.3. Tumor-Infiltrating Lymphocytes
13.2.2. Stem Cell Therapy
13.2.3. Natural Killer Cells
13.2.4. Dendritic Cells
13.2.5. Other Cell Therapies
13.3. Market Value Forecast By Origin, 2020-2034
13.3.1. Autologous Therapies
13.3.2. Allogenic Therapies
13.4. Market Value Forecast By Therapeutic Area, 2020-2034
13.4.1. Oncological Disorders
13.4.2. Autoimmune Disorders
13.4.3. Neurological Disorders
13.4.4. Others
13.5. Market Value Forecast By Country/Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Origin
13.6.3. By Therapeutic Area
13.6.4. By Country/Sub-region
14. Middle East & Africa Cell Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2020-2034
14.2.1. T-cell Therapy
14.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
14.2.1.2. T-cell Receptors
14.2.1.3. Tumor-Infiltrating Lymphocytes
14.2.2. Stem Cell Therapy
14.2.3. Natural Killer Cells
14.2.4. Dendritic Cells
14.2.5. Other Cell Therapies
14.3. Market Value Forecast By Origin, 2020-2034
14.3.1. Autologous Therapies
14.3.2. Allogenic Therapies
14.4. Market Value Forecast By Therapeutic Area, 2020-2034
14.4.1. Oncological Disorders
14.4.2. Autoimmune Disorders
14.4.3. Neurological Disorders
14.4.4. Others
14.5. Market Value Forecast By Country/Sub-region, 2020-2034
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Origin
14.6.3. By Therapeutic Area
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Bristol-Myers Squibb Company
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. IOVANCE Biotherapeutics, Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Janssen Biotech, Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. CellTrans, Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Gamida Cell Inc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Dendreon Pharmaceuticals LLC
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Kite Pharma, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Adaptimmune
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Takeda Pharmaceutical Company Limited
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments